Literature DB >> 32202961

RT-qPCR Methods to Support Pharmacokinetics and Drug Mechanism of Action to Advance Development of RNAi Therapeutics.

Elena Castellanos-Rizaldos1, Christopher R Brown1, Sean Dennin1, Joohwan Kim1, Swati Gupta1, Diana Najarian1, Yongli Gu1, Krishna Aluri1, Jennifer Enders1, Kirk Brown1, Yuanxin Xu1.   

Abstract

The goal of this study was to develop a reverse transcription quantitative polymerase chain reaction (RT-qPCR) method for the accurate quantification of chemically modified small interfering RNA (siRNA) including but not restricted to thermally destabilizing modifications such as glycol nucleic acid (GNA). RT-qPCR was found to be superior to mass spectrometry-based siRNA detection in terms of sensitivity and throughput. However, mass spectrometry is still the preferred method when specific metabolite detection is required and is also insensitive to siRNA chemical modifications such as GNA. The RT-qPCR approach can be optimized to take chemical modifications into account and works robustly in different matrices without optimization, unlike mass spectrometry. RT-qPCR and mass spectrometry both have their strengths and weaknesses for the detection of siRNA and must be used appropriately depending on the questions at hand. Considerations such as desired throughput, assay sensitivity, and metabolite identification must be weighed when choosing which methodology to apply.

Entities:  

Keywords:  RT-qPCR; pharmacodynamics; pharmacokinetics; small interfering RNA

Year:  2020        PMID: 32202961     DOI: 10.1089/nat.2019.0840

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  3 in total

1.  From bench to bedside: Improving the clinical safety of GalNAc-siRNA conjugates using seed-pairing destabilization.

Authors:  Mark K Schlegel; Maja M Janas; Yongfeng Jiang; Joseph D Barry; Wendell Davis; Saket Agarwal; Daniel Berman; Christopher R Brown; Adam Castoreno; Sarah LeBlanc; Abigail Liebow; Tara Mayo; Stuart Milstein; Tuyen Nguyen; Svetlana Shulga-Morskaya; Sarah Hyde; Sally Schofield; John Szeto; Lauren Blair Woods; Vedat O Yilmaz; Muthiah Manoharan; Martin Egli; Klaus Charissé; Laura Sepp-Lorenzino; Patrick Haslett; Kevin Fitzgerald; Vasant Jadhav; Martin A Maier
Journal:  Nucleic Acids Res       Date:  2022-06-23       Impact factor: 19.160

2.  Improvements to Hybridization-Ligation ELISA Methods to Overcome Bioanalytical Challenges Posed by Novel Oligonucleotide Therapeutics.

Authors:  Joseph A Haegele; Ramakrishna Boyanapalli; Jaya Goyal
Journal:  Nucleic Acid Ther       Date:  2022-04-11       Impact factor: 4.244

3.  Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates.

Authors:  Christopher R Brown; Swati Gupta; June Qin; Timothy Racie; Guo He; Scott Lentini; Ryan Malone; Mikyung Yu; Shigeo Matsuda; Svetlana Shulga-Morskaya; Anil V Nair; Christopher S Theile; Karyn Schmidt; Azar Shahraz; Varun Goel; Rubina G Parmar; Ivan Zlatev; Mark K Schlegel; Jayaprakash K Nair; Muthusamy Jayaraman; Muthiah Manoharan; Dennis Brown; Martin A Maier; Vasant Jadhav
Journal:  Nucleic Acids Res       Date:  2020-12-02       Impact factor: 16.971

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.